All Sauce from Weekly Sauce:

Liver disease can affect heart health and that includes even early forms of the disease, a new study reveals. While it had previously been known that nonalcoholic fatty liver disease was associated with cardiovascular death, the relationship was poorly understood, said researcher Dr. Alan Kwan. He is a cardiologist and cardiac imaging researcher in Cedars-Sinai…  read on >  read on >

With more American men turning to testosterone therapy as a way to boost energy levels, build muscle and tackle erectile dysfunction, it’s no wonder that web-based merchants have stepped into the breach, seeking to grab market share away from doctors and pharmacies. But are online testosterone purchases safe? No, a new investigation warns. The conclusion…  read on >  read on >

The updated bivalent COVID-19 boosters are now approved for use in children as young as 6 months of age, the U.S. Food and Drug Administration announced today. Children can receive either a Moderna or Pfizer-BioNTech bivalent booster shot, although the rules differ depending on their age and what type of vaccine they got as their…  read on >  read on >

Older adults who harbor more vitamin D in their brains may stay mentally sharper, a new study suggests. Researchers found that when older adults had higher levels of vitamin D in their brain tissue, they tended to perform better on standard tests of memory and thinking. They were also less likely to have dementia or…  read on >  read on >

A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven’t responded to other treatments, according to a pair of clinical trials. The targeted antibody drug — trastuzumab deruxtecan (T-DXd, sold under the brand name Enhertu) — dramatically outperformed an older antibody drug in one trial,…  read on >  read on >

An experimental therapy that uses the body’s own immune system cells may beat a standard treatment for patients with advanced melanoma, a new clinical trial finds. Researchers found that the therapy doubled the amount of time melanoma patients lived without their skin cancer progressing, versus a long-used drug called ipilimumab (Yervoy). The approach, called tumor-infiltrating…  read on >  read on >